Table 2.
Patients with marked hilar IgG4+ staining do not have a different clinical phenotype to those with lesser degrees of staining
| >50 IgG4+ plasma cells/HPF No. cases (%) | <50 IgG4+ plasma cells/HPF No. cases (%) | P-value | |
|---|---|---|---|
| Total | 19 (15.6) | 103 (84.4) | |
| Male gender | 16 (84.2) | 73 (70.9) | 0.25 |
| History of acute pancreatitis | 3 (15.8) | 5 (4.10) | 0.08 |
| Concomitant autoimmune disease* | 2 (10.5) | 23 (22.3) | 0.05 |
| History of IBD | 16 (84.2) | 65 (63.1) | 0.08 |
| Median age (years) at PSC diagnosis | 37.5; range 11–68 | 37; range 10–63 | 0.93 |
| Intrahepatic ductal involvement only | 6 (31.6) | 28 (27.2%) | 0.71 |
| Dominant stricture | 10 (52.6) | 25 (24.3) | 0.01 |
| Previous biliary stenting | 11 (57.9) | 22 (21.4) | 0.001 |
| Pretransplant MELD score | 14.3; range 9.2–22.5 | 14.4; range 8.2–26.7 | 0.99 |
| Cholangiocarcinoma‡ | 0 (0.0) | 5 (4.9%) | 0.32 |
| Median age (years) at transplant | 40.5; range 18–70 | 43; range 18–66 | 0.85 |
| Median time (years) to transplant after PSC diagnosis | 7; range 1–25 | 6; range 2–22 | 0.60 |
| PSC recurrence after transplant | 3 (15.6%) | 8 (7.8%) | 0.27 |
| All cause mortality after transplant | 3 (15.6%) | 23 (22.3%) | 0.84 |
a
Excluding inflammatory bowel disease (IBD).
b
Diagnosed on explant.